Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects

Hypertension

Volumn 25, Issue 4 I, 1995, Pages 602-609

  Burnier, Michel ^a,c   Hagman, Michael ^a   Nussberger, Jurg ^a   Biollaz, Jérôme ^a   Armagnac, Catherine ^b   Brouard, Rémi ^b   Waeber, Bernard ^a   Brunner, Hans R ^a  

^a Division of Hypertension   (Switzerland)

^b SANOFI   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

angiotensin II; natriuresis; receptors, angiotensin; renal circulation; uric acid

Indexed keywords

4 AMINOHIPPURIC ACID; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR; FRUCTAN; INULIN; IRBESARTAN; LONG ACTING DRUG; NEPHROTEST; POTASSIUM; RENIN; SODIUM; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ELECTROLYTE EXCRETION; GLOMERULUS FILTRATION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; MALE; NATRIURESIS; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BALANCE; URIC ACID URINE LEVEL;

EID: 0028960065     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.25.4.602     Document Type: Article

References (42)

1. Loutzenhiser R, Epstein M. The renal hemodynamic effects of calcium antagonists. In: Epstein M, Loutzenhiser R, eds. Calcium Antagonists and the Kidney. Philadelphia, Pa: Hanley & Belfus, Inc; 1990:33-74.
2. Luft FC, Fineberg NS, Weinberger MH. Long-term effect of nifedipine and hydrochlorothiazide on blood pressure and sodium homeostasis at varying levels of salt intake in mildly hypertensive patients. Am J Hypertens. 1991;4:752-760.
3. Ichikawa I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int. 1991;40:583-586.
4. Bühler FR, Laragh JH, Baer L, Vaughan ED Jr, Brunner HR. Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med. 1972;287:1209-1214.
5. Brunner HR. ACE inhibitors in renal disease. Kidney Int. 1992; 42:463-479.
6. Anderson S, Rennke HG, Brenner BM. Therapeutic advantages of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993-2000.
7. Keane WF, Anderson S, Aurell M, DeZeeuw D, Narins RG, Povar G. Angiotensin converting enzyme inhibitors and progressive renal insufficiency: current experience and future directions. Ann Intern Med. 1989;111:503-516.
8. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
9. Wexler RR, Carini DJ, Duncia JV, Johnson AL, Wells GJ, Chiu AT, Wong PC, Timmermans PBMWM. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens. 1992;5:209S-220S.
10. Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, Wexler RR, Yoo SE, Johnson AL, Timmermans PBMWM. Nonpeptide angiotensin II receptor antagonists, VII: cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:711-718.
11. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM. Nonpeptide angiotensin II antagonists, VIII: characterisation of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:719-725.
12. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM. Nonpeptide angiotensin II antagonists, IX: antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990; 252:726-732.
13. Burnier M, Brunner HR. Angiotensin II receptor antagonists and the kidney. Curr Opin Nephrol Hypertens. 1994;3:537-545.
14. Kon V, Fogo A, Ichikawa I, Hellings SE, Bills T. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int. 1993;44:545-550.
15. Tanaka R, Kon V, Yoshioka T, Ichikawa I, Fogo A. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int. 1994;45:537-543.
16. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, Brunner HR. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22: 339-347.
17. Ribstein J, Sissmann J, Picard A, Bouroudian M, Mimran A. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens. 1994;12(suppl 3):131. Abstract.
18. Harrison HE. A modification of the diphenylamine method for the determination of inulin. Proc Soc Exp Biol Med. 1942;49:111-114.
19. Friedman SM, Polley JR, Friedman CL. The clearance of inulin and sodium p-aminohippurate in the rat. Am J Physiol. 1947;150: 340-352.
20. Magnin JL, Munafo A, Steinhauslin F, Burnier M, Diezi J, Biollaz J. Endogenous lithium: a new tool in nephrology. Experientia. 1991; 47:A30. Abstract.
21. Miller N, Durr JA, Alfrey AC. Measurement of endogenous lithium levels in serum and urine by electrothermal atomic absorption spectrometry: a method with potential clinical application. Anal Biochem. 1989;182:245-249.
22. Nussberger J, Waeber B, Brunner HR, Burris JF, Vetter W. Highly sensitive microassay for aldosterone in unextracted plasma: comparison with two other methods. J Lab Clin Med. 1984;104:789-796.
23. Nussberger J, Fasanella d'Amore T, Porchet M, Waeber B, Brunner DB, Brunner HR, Kler L, Brown AN, Francis RJ. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. J Cardiovasc Pharmacol. 1987; 9:39-44.
24. Nussberger J, Keller I, Waeber B, Brunner HR. Angiotensin II measurement with high affinity monoclonal antibodies. J Hypertens. 1988;6(suppl 4):S424-S425.
25. 8-angiotensin II for understanding and treatment of high blood pressure. Lancet. 1973;2:1045-1048.
26. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PBMWM, Brunner HR. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991;83:1333-1342.
27. Munafo H, Christen Y, Nussberger J, Shum LY, Borland RM, Lee RJ, Waeber B, Biollaz J, Brunner HR. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 1992;51:513-521.
28. Doig JK, MacFaden RJ, Sweet CS, Lees KR, Reid JL. Dose-ranging study of the angiotensin type 1 receptor antagonist losartan (DuP 753/MK954), in salt-deplete normal man. J Cardiovasc Pharmacol. 1993;21:732-738.
29. Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, Roccon A, Galindo G, Barthelemy G, Gautret B, Bernhart C, Perreaut P, Brelière JC, Le Fur G, Nisato D. Pharmacological characterisation of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1993;265:826-834.
30. Lacour C, Roccon A, Cazaubon C, Segondy D, Nisato D. Pharmacological study of SR 47436, a non-peptide angiotensin II AT1-receptor antagonist, in conscious monkeys. J Hypertens. 1993;11: 1187-1194.
31. Hollenberg NK, Meggs LG, Williams GH, Katz J, Garnic JD, Harrington DP. Sodium intake and renal responses to captopril in normal man and in essential hypertension. Kidney Int. 1981;20:240-245.
32. Fenoy FJ, Milicic I, Smith RD, Wong PC, Timmermans PBMWM, Roman R. Effects of Dup 753 on renal function of normotensive and spontaneously hypertensive rats. Am J Hypertens. 1991;4: 321S-326S.
33. Bovee KC, Wong PC, Timmermans PBMWM, Thoolen MJMC. Effects of nonpeptide angiotensin II receptor antagonist DuP 753 on blood pressure and renal functions in spontaneously hypertensive PH dogs. Am J Hypertens. 1991;4:327S-333S.
34. Gansevoort RT, De Zeeuw D, De Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45:861-867.
35. Loutzenhiser R, Epstein M, Hayashi K, Takenada T, Forster H. Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: studies in isolated perfused hydronephrotic kidneys. Am J Hypertens. 1991;4:309S-314S.
36. Zhuo J, Thomas D, Harris PJ, Skinner SL. The role of endogenous angiotensin II in the regulation of renal haemodynamics and proximal fluid reabsorption in the rat. J Physiol (Lond). 1992; 453:1-13.
37. Xie MH, Liu FY, Wong PC, Timmermans PBMWM, Cogan MG. Proximal nephron and renal effects of Dup 753, a nonpeptide angiotensin II receptor antagonist. Kidney Int. 1990;38:473-479.
38. McNabb WR, Noormohamed FH, Brooks BA, Till AE, Lant AF. Effects of repeated doses of enalapril and renal function in man. Br J Clin Pharmacol. 1985;19:353-361.
39. Strocchi E, Malini PL, Ambrosioni E. Lisinopril and renal tubular function. J Hypertens. 1987;5(suppl 5):S401-S402.
40. Mendelsohn FAO. Localization and properties of angiotensin receptors. J Hypertens. 1985;3:307-316.
41. Nakashima M, Uematsu T, Kosuge K, Kanamura M. Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992;42: 333-335.
42. Burnier M, Biollaz J, Magnin JL, Bidlingmeyer M, Brunner HR. Renal sodium handling in patients with untreated hypertension and white coat hypertension. Hypertension. 1994;23:496-502.